1. Home
  2. Africa
  • News

Generic anti-AIDS drugs withdrawn from WHO list

Drugs - Antiretrovirals IRIN
In a move that could affect HIV-positive people on treatment in developing countries, an Indian generic drug manufacturer voluntarily withdrew its drugs from the World Health Organisation's (WHO) list of approved HIV medicines. The seven antiretroviral (ARV) drugs made by Ranbaxy Laboratories were removed after the company "found discrepancies" in documents proving their biological equivalence to the patented versions, a WHO statement said. In August this year, WHO withdrew three other drugs made by the company for the same reason. The impact of Ranbaxy's decision on African countries embarking on treatment initiatives remains unclear. "Of course, we are worried about the disruption of ARV programmes, particularly in developing countries - many have already ordered large quantities of drugs," WHO spokeswoman Daniela Bagozzi told PlusNews. However, this did not mean there were "any real problems" with the drugs in terms of safety. The problem was that the medicines "may or may not offer the same therapeutic benefits" as the originals on which they were based, she noted. WHO has advised that patients on treatment should discontinue using the de-listed drugs, but recommended that when alternative quality-controlled treatment could not be immediately found, patients should continue on the drug regimen, as interrupting treatment was "more dangerous". According to Bagozzi, the WHO delisting did not bind countries to ban the Ranbaxy products. It was up to individual countries and their drug regulatory authorities to decide whether to continue using the drugs or not. But countries relying on Global AIDS Fund resources for their treatment programmes would not be able to continue using the drugs, as the Fund has stipulated that only WHO-approved ARVs were to be used. African treatment programmes funded by the Global Fund and using Ranbaxy drugs are: Benin, Central African Republic, Cote d'Ivoire, Malawi and Swaziland. "Of all the HIV/AIDS grants we've given out, we estimate that about 10 countries are currently using Ranbaxy products," Global Fund spokesman Tim Clark, told PlusNews. Meanwhile, Ranbaxy's announcement was unlikely to have "much of an impact" on Medecins Sans Frontieres' (MSF) treatment project in South Africa, as the initiative only used two of their drugs, and these could easily be replaced, Marta Darder, the MSF coordinator for access to essential medicines, told PlusNews. For more information on the practical implications of the withdrawal of the Ranbaxy drugs from the WHO list: http://mednet3.who.int/

This article was produced by IRIN News while it was part of the United Nations Office for the Coordination of Humanitarian Affairs. Please send queries on copyright or liability to the UN. For more information: https://shop.un.org/rights-permissions

Share this article

Get the day’s top headlines in your inbox every morning

Starting at just $5 a month, you can become a member of The New Humanitarian and receive our premium newsletter, DAWNS Digest.

DAWNS Digest has been the trusted essential morning read for global aid and foreign policy professionals for more than 10 years.

Government, media, global governance organisations, NGOs, academics, and more subscribe to DAWNS to receive the day’s top global headlines of news and analysis in their inboxes every weekday morning.

It’s the perfect way to start your day.

Become a member of The New Humanitarian today and you’ll automatically be subscribed to DAWNS Digest – free of charge.

Become a member of The New Humanitarian

Support our journalism and become more involved in our community. Help us deliver informative, accessible, independent journalism that you can trust and provides accountability to the millions of people affected by crises worldwide.

Join